Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence
Titel:
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence
Auteur:
Harrington, K.J. Cohen, E.E.W. Soulières, D. Dinis, J. Licitra, L. Ahn, M.-J. Soria, A. Machiels, J.-P. Mach, N. Mehra, R. Burtness, B. Swaby, R.F. Lin, J. Ge, J. Lerman, N. Tourneau, C. Le